{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:50:53Z","timestamp":1790866253134,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.bcp.2011.07.077","type":"journal-article","created":{"date-parts":[[2011,7,24]],"date-time":"2011-07-24T18:11:03Z","timestamp":1311531063000},"page":"1528-1539","source":"Crossref","is-referenced-by-count":46,"title":["New antimicrobial agents on the horizon"],"prefix":"10.1016","volume":"82","author":[{"given":"Karen","family":"Bush","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Pucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2011.07.077_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bcp.2011.07.077_bib0010","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.coph.2008.04.009","article-title":"Recent advances in topoisomerase inhibitors","volume":"8","author":"Bradbury","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.bcp.2011.07.077_bib0015","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1021\/cr030101q","article-title":"Bacterial topoisomerase inhibitors: quinolone and pyridine antibacterial agents","volume":"105","author":"Mitscher","year":"2005","journal-title":"Chem Rev"},{"key":"10.1016\/j.bcp.2011.07.077_bib0020","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1517\/13543776.2010.505922","article-title":"New quinolone antibiotics: a survey of the literature from 2005 to 2010","volume":"20","author":"Wiles","year":"2010","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bcp.2011.07.077_bib0025","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1128\/AAC.01374-09","article-title":"In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone","volume":"54","author":"Morrow","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0030","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1128\/AAC.01197-09","article-title":"Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates","volume":"54","author":"Lauderdale","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0035","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1128\/AAC.00078-09","article-title":"In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2440 clinical isolates","volume":"53","author":"Adam","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0040","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1093\/jac\/dkq341","article-title":"In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone","volume":"65","author":"Li","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0045","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1128\/AAC.00683-09","article-title":"Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers","volume":"54","author":"Chung","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0050","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/jac\/dkh180","article-title":"Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492","volume":"53","author":"Harnett","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0055","unstructured":"Rib-X Company Website, http:\/\/www.rib-x.com."},{"key":"10.1016\/j.bcp.2011.07.077_bib0060","series-title":"Proceedings of the 45th interscience conference on antimicrobial agents and chemotherapy","article-title":"Minimum inhibitory concentrations (MIC) and mutation prevention concentrations (MPC) of NXL101, a novel topoisomerase IV inhibitor, against Staphylococcus aureus including multi-resistant strains","author":"Levasseur","year":"2005"},{"key":"10.1016\/j.bcp.2011.07.077_bib0065","series-title":"Proceedings of the 46th interscience conference on antimicrobial agents and chemotherapy","article-title":"Efficacy of NXL101, a novel topoisomerase inhibitor, against multi-resistant Staphylococcus aureus in murine septicaemia and thigh muscle infections","author":"Lowther","year":"2006"},{"key":"10.1016\/j.bcp.2011.07.077_bib0070","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1128\/AAC.00496-08","article-title":"Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases","volume":"52","author":"Black","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/13543780903473150","article-title":"Discontinued drugs in 2008: anti-infectives","volume":"19","author":"Ryder","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bcp.2011.07.077_bib0080","first-page":"379","article-title":"Structure-activity relationships in quinolone antibacterials: design, synthesis, and biological activities of novel isothiazoloquinolones","volume":"14","author":"Chu","year":"1988","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.bcp.2011.07.077_bib0445","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1128\/AAC.01666-10","article-title":"In vitro and In VIVO PROfile of ACH-702, an isothiazoloquinolone, against bacterial pathogens","volume":"55","author":"Pucci","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0090","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1128\/AAC.01321-06","article-title":"In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase\/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant Gram-positive and fastidious organism groups","volume":"51","author":"Huband","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0095","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.bmcl.2006.12.005","article-title":"Structure-activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors","volume":"17","author":"Tran","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bcp.2011.07.077_bib0100","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1128\/AAC.00113-09","article-title":"Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV","volume":"53","author":"Pan","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0105","doi-asserted-by":"crossref","first-page":"6435","DOI":"10.1021\/jm060505l","article-title":"3-Aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms","volume":"49","author":"Ellsworth","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2011.07.077_bib0110","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1128\/AAC.50.4.1228-1237.2006","article-title":"In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class","volume":"50","author":"Mani","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0115","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/AAC.00596-06","article-title":"Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds","volume":"51","author":"Grossman","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0120","first-page":"146","article-title":"Fatty acid biosynthesis as a target for novel antibacterials","volume":"5","author":"Heath","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.bcp.2011.07.077_bib0125","doi-asserted-by":"crossref","first-page":"17541","DOI":"10.1074\/jbc.R600004200","article-title":"Inhibiting bacterial fatty acid synthesis","volume":"281","author":"Zhang","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2011.07.077_bib0130","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature04784","article-title":"Platensimycin is a selective FabF inhibitor with potent antibiotic properties","volume":"441","author":"Wang","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2011.07.077_bib0135","doi-asserted-by":"crossref","first-page":"7612","DOI":"10.1073\/pnas.0700746104","article-title":"Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties","volume":"104","author":"Wang","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2011.07.077_bib0140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nature07772","article-title":"Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens","volume":"458","author":"Brinster","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2011.07.077_bib0145","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1128\/AAC.46.10.3118-3124.2002","article-title":"Discovery of a novel and potent class of FabI-directed antibacterial agents","volume":"46","author":"Payne","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0150","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1128\/AAC.01254-06","article-title":"In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis","volume":"51","author":"Karlowsky","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0155","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1128\/AAC.00400-09","article-title":"AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity","volume":"53","author":"Karlowsky","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0160","series-title":"Proceedings of the 47th interscience conference on antimicrobial agents and chemotherapy","article-title":"Efficacy of AFN-1252 and vancomycin in the mouse subcutaneous abscess with a methicillin-resistant S. aureus","author":"Weiss","year":"2007"},{"key":"10.1016\/j.bcp.2011.07.077_bib0165","series-title":"Proceedings of the 46th interscience conference on antimicrobial agents and chemotherapy","article-title":"In vivo pharmacodynamic profiling of API-1252 against Staphylococcus aureus in a murine thigh model","author":"Banevicius","year":"2006"},{"key":"10.1016\/j.bcp.2011.07.077_bib0170","first-page":"513","article-title":"Drug forecast\u2014the peptide deformylase inhibitors as antibacterial agents","volume":"3","author":"Guay","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.bcp.2011.07.077_bib0175","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.coph.2006.06.003","article-title":"Peptide deformylase as an antibacterial target: a critical assessment","volume":"6","author":"Leeds","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.bcp.2011.07.077_bib0180","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/j.1460-2075.1994.tb06335.x","article-title":"Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation","volume":"13","author":"Mazel","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.bcp.2011.07.077_bib0185","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1172\/JCI200422269","article-title":"Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics","volume":"114","author":"Lee","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2011.07.077_bib0190","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1128\/AAC.44.7.1825-1831.2000","article-title":"Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene","volume":"44","author":"Margolis","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0195","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1128\/AAC.48.12.4835-4842.2004","article-title":"Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor","volume":"48","author":"Ramanathan-Girish","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0200","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1128\/AAC.00026-09","article-title":"In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models","volume":"53","author":"Osborne","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0205","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1128\/CMR.00030-10","article-title":"Challenges of antibacterial discovery","volume":"24","author":"Silver","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.bcp.2011.07.077_bib0210","series-title":"Proceedings of the 50th interscience conference on antimicrobial agents and chemotherapy","article-title":"In vitro activity of GSK1322322, a novel peptide deformylase Inhibitor, against 4,836 pathogens from skin and soft tissue infections and respiratory tract infections","author":"Bouchillon","year":"2010"},{"key":"10.1016\/j.bcp.2011.07.077_bib0215","unstructured":"US National Institutes of Health Clinical Trials Website, http:\/\/clinicaltrials.gov\/ct2\/home."},{"key":"10.1016\/j.bcp.2011.07.077_bib0220","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/cbic.200900779","article-title":"The future of aminoglycosides: the end or renaissance?","volume":"11","author":"Houghton","year":"2010","journal-title":"Chembiochem"},{"key":"10.1016\/j.bcp.2011.07.077_bib0225","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.mib.2010.09.004","article-title":"Combating evolution with intelligent design: the neoglycoside ACHN-490","volume":"13","author":"Armstrong","year":"2010","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.bcp.2011.07.077_bib0230","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1128\/AAC.00572-10","article-title":"Synthesis and spectrum of the neoglycoside ACHN-490","volume":"54","author":"Aggen","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0235","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/jac\/dkq408","article-title":"Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates","volume":"66","author":"Livermore","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0240","series-title":"Proceedings of the 48th annual meeting of the Infectious Diseases Society of America, Vancouver, British Columbia, Canada","article-title":"Efficacy of ACHN-490 in a murine urinary tract infection model with Escherichia coli","author":"Pulse","year":"2010"},{"key":"10.1016\/j.bcp.2011.07.077_bib0245","unstructured":"Achaogen Company Website, http:\/\/www.achaogen.com."},{"key":"10.1016\/j.bcp.2011.07.077_bib0250","unstructured":"SelectX Pharmaceuticals Company Website, http:\/\/www.selectxpharm.com."},{"key":"10.1016\/j.bcp.2011.07.077_bib0255","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/dkf085","article-title":"In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis","volume":"50","author":"Schmitz","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0260","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1592\/phco.30.3.290","article-title":"Cethromycin: a promising new ketolide antibiotic for respiratory infections","volume":"30","author":"Rafie","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bcp.2011.07.077_bib0265","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/jac\/dkp231","article-title":"In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008","volume":"64","author":"Patel","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0270","unstructured":"CDER Company Website. Summary Minutes of the Anti-Infective Drugs Advisory Committee; June 8, 2009, Freedom of Information Office, FDA, http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM183844.pdf."},{"key":"10.1016\/j.bcp.2011.07.077_bib0275","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jinf.2010.08.010","article-title":"The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009)","volume":"61","author":"Farrell","year":"2010","journal-title":"J Infect"},{"key":"10.1016\/j.bcp.2011.07.077_bib0280","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1128\/AAC.01123-09","article-title":"In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms","volume":"54","author":"McGhee","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0285","unstructured":"Cempra Company Website, http:\/\/www.cempra.com\/research\/antibacterials\/."},{"key":"10.1016\/j.bcp.2011.07.077_bib0290","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1128\/AAC.00714-10","article-title":"Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3","volume":"54","author":"Locke","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0295","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1128\/AAC.01569-09","article-title":"Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges","volume":"54","author":"Brown","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0300","unstructured":"Trius Company Website, http:\/\/triusrx.com\/."},{"key":"10.1016\/j.bcp.2011.07.077_bib0305","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/AAC.00076-10","article-title":"A phase 2 randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections (cSSSI)","volume":"55","author":"Prokocimer","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0310","unstructured":"Rib-X Company Website, http:\/\/www.rib-x.com\/."},{"key":"10.1016\/j.bcp.2011.07.077_bib0315","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1128\/AAC.01383-07","article-title":"In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens","volume":"52","author":"Lawrence","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"January (1)","key":"10.1016\/j.bcp.2011.07.077_bib0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bcp.2011.07.077_bib0325","series-title":"Abstract 2439 43rd interscience conference on antimicrobial agents and chemotherapy","article-title":"In vitro activity of PTK0796 (BAY 73-6944) against Gram-positive and Gram-negative organisms","author":"Macone","year":"2003"},{"key":"10.1016\/j.bcp.2011.07.077_bib0330","series-title":"Abstr. 2458 43rd interscience conference on antimicrobial agents and chemotherapy","article-title":"PTK 0796 (BAY 73-6944): in vitro potency and spectrum of activity compared to ten other antimicrobial compounds","author":"Traczewski","year":"2003"},{"key":"10.1016\/j.bcp.2011.07.077_bib0335","first-page":"929","article-title":"Outpatient parenteral antimicrobial therapy: recent developments and future prospects","volume":"11","author":"Torok","year":"2010","journal-title":"Cur Opin Investig Drugs"},{"key":"10.1016\/j.bcp.2011.07.077_bib0340","first-page":"743","article-title":"Interscience conference on antimicrobial agents and chemotherapy\u201450th annual meeting\u2014research on promising new agents: part 1","volume":"13","author":"Walker","year":"2010","journal-title":"IDrugs"},{"key":"10.1016\/j.bcp.2011.07.077_bib0345","unstructured":"Tetraphase Company Website, www.tphase.com."},{"key":"10.1016\/j.bcp.2011.07.077_bib0350","series-title":"50th interscience conference on antimicrobial agents and chemotherapy","article-title":"TP-434 is a novel broad-spectrum fluorocycline. Poster F1-2157","author":"Hunt","year":"2010"},{"key":"10.1016\/j.bcp.2011.07.077_bib0355","series-title":"50th interscience conference on antimicrobial agents and chemotherapy","article-title":"TP-434 is highly efficacious in animal models of infection, poster F1-2161","author":"Murphy","year":"2010"},{"issue":"September","key":"10.1016\/j.bcp.2011.07.077_bib0360","first-page":"561","article-title":"New molecules from old classes: revisiting the development of beta-lactams","volume":"12","author":"Page","year":"2009","journal-title":"IDrugs"},{"key":"10.1016\/j.bcp.2011.07.077_bib0365","unstructured":"Jacoby GA. Bush K company website, \u03b2-Lactamase classification and amino acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor resistant enzymes; 2011 April 12, 2011, http:\/\/www.lahey.org\/Studies\/."},{"issue":"June","key":"10.1016\/j.bcp.2011.07.077_bib0370","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1128\/AAC.01525-09","article-title":"In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli","volume":"54","author":"Page","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0375","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/jac\/dkq310","article-title":"Activity of BAL30376 (monobactam BAL19764+BAL29880+clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms","volume":"65","author":"Livermore","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0380","series-title":"Abstr. F1-2129 50th interscience conference on antimicrobial agents and chemotherapy","article-title":"In vitro antibacterial activity of MC-1: a new siderophore-monocarbam conjugate versus recent Gram-negative bacterial clinical isolates","author":"Huband","year":"2010"},{"key":"10.1016\/j.bcp.2011.07.077_bib0385","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jac\/dkp197","article-title":"In vitro activity of the \u03b2-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases","volume":"64","author":"Stachyra","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0390","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/jac\/dkq306","article-title":"In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters","volume":"65","author":"Mushtaq","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0395","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/jac\/dkq161","article-title":"Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae","volume":"65","author":"Mushtaq","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0400","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/AAC.00860-06","article-title":"In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa","volume":"51","author":"Takeda","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0405","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/jac\/dkq248","article-title":"Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae","volume":"65","author":"Livermore","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0410","series-title":"Abstr. F1-2139 50th interscience conference on antimicrobial agents and chemotherapy","article-title":"In vitro activity of the class A and C (-lactamase inhibitor MK-7655","author":"Young","year":"2010"},{"key":"10.1016\/j.bcp.2011.07.077_bib0415","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1517\/13543776.2010.515588","article-title":"New \u03b2-lactam antibiotics and \u03b2-lactamase inhibitors","volume":"20","author":"Bush","year":"2010","journal-title":"Exp Opin Therapeut Pat"},{"key":"10.1016\/j.bcp.2011.07.077_bib0420","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.2174\/156802610793176620","article-title":"Efflux pumps of Gram-negative bacteria, a new target for new molecules","volume":"10","author":"Pages","year":"2010","journal-title":"Curr Topics Med Chem"},{"key":"10.1016\/j.bcp.2011.07.077_bib0425","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrd2200","article-title":"Waltzing transporters and \u2018the dance macabre\u2019 between humans and bacteria","volume":"6","author":"Lomovskaya","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bcp.2011.07.077_bib0430","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1128\/AAC.00530-10","article-title":"Cationic amphiphiles, a new generation of antimicrobials inspired by the natural antimicrobial peptide scaffold","volume":"54","author":"Findlay","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.07.077_bib0435","doi-asserted-by":"crossref","first-page":"D933","DOI":"10.1093\/nar\/gkn823","article-title":"APD2: the updated antimicrobial peptide database and its application in peptide design","volume":"37","author":"Wang","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bcp.2011.07.077_bib0450","unstructured":"http:\/\/anacor.com\/gsk052.php."},{"key":"10.1016\/j.bcp.2011.07.077_bib0440","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2202","article-title":"Multi-targeting by monotherapeutic antibacterials","volume":"6","author":"Silver","year":"2007","journal-title":"Nat Rev Drug Discov"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295211005351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295211005351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T08:04:36Z","timestamp":1560413076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295211005351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":89,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0006295211005351"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2011.07.077","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}